Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.57 |
| ▸ | PREP | P48147 | 6/20 | 0.51 |
| ▸ | FAP | Q12884 | 5/20 | 0.51 |
| ▸ | CCR3 | P51677 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000474 | 0.92 | CHRM2 (0.55) | CHRM2PREPFAPSYKCYP2C9 | |
| SCHEMBL16002921 | 0.88 | CHRM2 (0.52) | CHRM2PREPFAPCCR3SYK | |
| SCHEMBL16000488 | 0.82 | SYK (0.49) | CHRM2PREPFAPSYK | |
| SCHEMBL21384595 | 0.82 | CHRM2 (0.54) | CHRM2PREPFAPCCR3PDE2A | |
| SCHEMBL13826416 | 0.80 | ALDH1A1 (0.56) | CHRM2 | |
| SCHEMBL31395273 | 0.80 | KMT2A (0.60) | CHRM2CCR3PDE2ACYP2C9 | |
| SCHEMBL16002957 | 0.80 | CHRM2 (0.52) | CHRM2PREPCCR3SYKCYP2C9 | |
| SCHEMBL16000500 | 0.79 | CHRM2 (0.54) | CHRM2CCR3SYKPDE2A | |
| SCHEMBL21381377 | 0.78 | CHRM2 (0.57) | CHRM2FAPCCR3SYKPDE2A | |
| SCHEMBL21384601 | 0.76 | IDO1 (0.54) | CHRM2CCR3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
| WO-2012154518-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | CHRM2 788/4885PREP 542/4885FAP 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.